IRB #H-40102/ BMC #Etoposide in COVID: A Phase II Single-Center, Randomized, Open-Label, Safety and Efficacy Study of Etoposide in Patients with COVID-19 Infection

WIRB #H-40222/ Incyte #INCB-369 (RUXCOVID-DEVENT): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19–Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) (temp closure)

IRB #H-40344/ BWH #ESCAPE: ESCAPE (Evaluation of SARS-CoV-2 Antibody-containing Plasma thErapy): A Prospective, Randomized, Double-Masked, Placebo-Controlled Trial of High-Titer COVID-19 Convalescent Plasma (HT-CCP) for the Treatment of Hospitalized Patients with COVID-19 of Moderate Severity (pending IRB approval)